Objective   To evaluate the efficiency of lamivudine combined with hepatitis B immunoglobulin to prevent hepatitis B recurrence after liver transplantation.    Methods   The literature concerning the application of lamivudine and hepatitis B immunoglobulin after liver transplantation was collected. The efficacy of initial lamivudine

and hepatitis B immunoglobulin alone or combined together was evaluated in liver transplantation recipients with hepatitis B by performing a systematic review of the literature with a Meta-analysis of clinical trials. Odds ratio (OR) was applied to evaluate the effect of therapeutic alliance to decrease the reinfection rate whether or not.    Results   We identified 7 clinical trials

and there were 360 patients subjected. OR and 95% confidence interval (95%CI) was 0.34 (95％CI ranging from 0.18 to 0.64). For overall test result

Z value was 3.33 and P value was 0.01. The P value was 0.310 for our test of study homogeneity.    Conclusion   Our meta-analysis shows that lamivudine or hepatis B immunoglobulin can effective prevent hepatitis B recurrence after liver transplantation

and therapeutic alliance is more effective than monotherapy

and tolerance to lamivudine or hepatis B immunoglobulin was good.